---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-248189"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:41:11.202076+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Repligen appoints Olivier Loeillot as President and CCO; Hunt remains CEO

## Summary
- Loeillot appointed President and Chief Commercial Officer effective Oct 2, 2023; reports to CEO Tony Hunt.
- Base salary $600k, target bonus 75% of base, signing bonus $1.35M, equity $4M vesting over 5 years.
- Hunt relinquishes President role effective Oct 2 but remains CEO; Loeillot has 20+ yr bioprocess experience from Cytiva/GE and Lonza.

## SEC filing metadata
- accession: 0001193125-23-248189
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/0001193125-23-248189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/d463559d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-248189
- JSON: https://secwatch.observer/filing/0001193125-23-248189.json
- Plain text: https://secwatch.observer/filing/0001193125-23-248189.txt

## Key facts
- Executive change
  Tony Hunt changed role as President at REPLIGEN CORP.
  - Action: relinquish
  - Role: President
  source text: In connection with Mr. Hunt’s and the rest of the Board’s appointment of Mr. Loeillot’s as President and Chief Commercial Officer, Mr. Hunt will relinquish his role of President, effective October 2, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/0001193125-23-248189-index.htm
- Executive change
  Olivier Loeillot was appointed as President and Chief Commercial Officer at REPLIGEN CORP.
  - Action: appointed
  - Role: President and Chief Commercial Officer
  source text: On October 2, 2023, Repligen Corporation (the “Company”) announced that Olivier Loeillot would be joining the Company as its President and Chief Commercial Officer, effective October 2, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/730272/000119312523248189/0001193125-23-248189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.